[go: up one dir, main page]

WO2012005550A3 - 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 - Google Patents

담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 Download PDF

Info

Publication number
WO2012005550A3
WO2012005550A3 PCT/KR2011/005033 KR2011005033W WO2012005550A3 WO 2012005550 A3 WO2012005550 A3 WO 2012005550A3 KR 2011005033 W KR2011005033 W KR 2011005033W WO 2012005550 A3 WO2012005550 A3 WO 2012005550A3
Authority
WO
WIPO (PCT)
Prior art keywords
gallbladder carcinoma
treating
carcinoma
metastasis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/005033
Other languages
English (en)
French (fr)
Other versions
WO2012005550A2 (ko
Inventor
홍효정
김진만
정문식
윤현호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Publication of WO2012005550A2 publication Critical patent/WO2012005550A2/ko
Publication of WO2012005550A3 publication Critical patent/WO2012005550A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법에 관한 것이다. 본 발명의 담낭암 세포 표면의 L1CAM 단백질을 인식하며 담낭암 조직에 특이적으로 결합하는 항체 또는 siRNA, shRNA 또는 안티센스 올리고뉴클레오티드 및 이를 포함하는 약제학적 조성물은 담낭암의 성장, 침윤 및 이동을 억제 및 세포 사멸을 유도할 수 있으므로, 보다 안전하면서도 효과적인 담낭암의 예방 및 치료에 널리 활용될 수 있을 것이다.
PCT/KR2011/005033 2010-07-08 2011-07-08 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 Ceased WO2012005550A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100066055 2010-07-08
KR10-2010-0066055 2010-07-08

Publications (2)

Publication Number Publication Date
WO2012005550A2 WO2012005550A2 (ko) 2012-01-12
WO2012005550A3 true WO2012005550A3 (ko) 2012-04-26

Family

ID=45441681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005033 Ceased WO2012005550A2 (ko) 2010-07-08 2011-07-08 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법

Country Status (2)

Country Link
KR (1) KR101271964B1 (ko)
WO (1) WO2012005550A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
WO2011096534A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR101984554B1 (ko) 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
HUE033149T2 (en) 2011-08-04 2017-11-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
EP2818481B1 (en) 2012-02-21 2019-08-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
EP2824114B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PL2876446T3 (pl) 2012-07-19 2019-06-28 Toray Industries, Inc. Sposób wykrywania nowotworu
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR20190036553A (ko) * 2016-08-02 2019-04-04 메모리얼 슬로안 케터링 캔서 센터 전이성 암의 치료 및 전이성 질환에 대한 모델 시스템
KR20180079232A (ko) * 2016-12-30 2018-07-10 강원대학교산학협력단 L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931976B1 (ko) * 2006-08-23 2009-12-15 한국생명공학연구원 담도암 치료용 약제학적 조성물 및 이를 이용한 담도암의성장, 전이 억제 및 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100060351A (ko) * 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931976B1 (ko) * 2006-08-23 2009-12-15 한국생명공학연구원 담도암 치료용 약제학적 조성물 및 이를 이용한 담도암의성장, 전이 억제 및 치료 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. SEBENS MUERKOSTER ET AL.: "Drug-induced expression of the cellular adhension molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells", ONCOGENE, vol. 26, no. 19, 2007, pages 2759 - 2768, XP002436286, DOI: doi:10.1038/sj.onc.1210076 *
SHIDENG BAO ET AL.: "Targeting cancer stem cells through L1CAM suppresses glioma growth", CANCER RESEARCH, vol. 68, no. 15, 2008, pages 6043 - 6048 *

Also Published As

Publication number Publication date
KR20120005412A (ko) 2012-01-16
WO2012005550A2 (ko) 2012-01-12
KR101271964B1 (ko) 2013-06-07

Similar Documents

Publication Publication Date Title
WO2012005550A3 (ko) 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2013059396A3 (en) Treatment of cancer with tor kinase inhibitors
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2012062925A3 (en) Compounds and methods for treating pain
TN2009000521A1 (en) Rnai inhibition of alpha-enac expression
WO2010056309A3 (en) Methods and compositions related to targeting monoacylglycerol lipase
WO2008025025A3 (en) Antisense composition and method for inhibition of mirna biogenesis
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
WO2012068405A3 (en) Modulation of alpha synuclein expression
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2008082887A3 (en) Inhibitors of poly(adp-ribose)polymerase
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2009158374A3 (en) Inhibitors of akt activity
WO2009143292A9 (en) Method of treating pneumoconiosis with oligodeoxynucleotides
WO2010085151A3 (en) Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
TWI369590B (en) Treatment liquid for resist substrate, and method of treating resist substrate using the same
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
WO2010015965A3 (en) Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
WO2009102789A3 (en) Use of rxr agonists for the treatment of osteroarthritis
CA2810119C (en) Clec14a inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11803836

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11803836

Country of ref document: EP

Kind code of ref document: A2